Follicular lymphoma trials in China

In China 52 Also abroad 188

52 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular Lymphoma
Where
Beijing
Age
18 years and over
People
65
Run by
Evopoint Biosciences Inc.
See details and how to joinNCT07545603
No phaseNot yet taking people in China
A Study to Evaluate MTM-H-001 Injection in Adult Participants With Relapsed or Refractory B-cell Malignancies
Where
Langfang
Age
18 years to 75 years
People
69
Run by
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT07476378
Phase 1/2Taking people
Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
Where
Beijing
Age
8 years to 85 years
People
85
Run by
Essen Biotech
See details and how to joinNCT07410494
Phase 2Taking people
Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma
Where
Nanjing
Age
18 years to 75 years
People
33
Run by
The First Affiliated Hospital with Nanjing Medical University
See details and how to joinNCT07418190
Phase 1/2Taking people
Evaluate the Safety and Clinical Activity of HH2853
Where
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Linyi, Nanjing, Nanning, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Zhengzhou
Age
18 years and over
People
254 worldwide
Run by
Haihe Biopharma Co., Ltd.
See details and how to joinNCT04390737
Phase 3Not yet taking people in China
IMM0306 in Combination With Lenalidomide vs Placebo in Combination With Lenalidomide in Patients With Relapsed/Refractory Follicular Lymphoma
Where
Beijing
Age
18 years and over
People
198
Run by
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
See details and how to joinNCT07355283
Phase 2Taking people
Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma
Where
Guangzhou
Age
18 years to 70 years
People
30
Run by
Sun Yat-sen University
See details and how to joinNCT07077512
Phase 3Not yet taking people in China
Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma
Where
Beijing, Changsha, Chongqing, Dalian, Guangzhou, Guiyang, Haikou, Harbin, Kunming, Lanzhou, Linyi, Nanchang, Nanjing, Shanghai, Shenyang, Taiyuan, Tianjin, Ürümqi, Wuhan, Xi’an, Yantai, Yinchuan, Zhengzhou
Age
18 years to 80 years
People
228
Run by
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
See details and how to joinNCT07187960
Early phase 1Not yet taking people in China
Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma
Where
Xi'an
Age
18 years and over
People
3
Run by
First Affiliated Hospital Xi'an Jiaotong University
See details and how to joinNCT07168291
No phaseTaking people
Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular Lymphoma
Where
Nanjing
Age
18 years to 75 years
People
15
Run by
The First Affiliated Hospital with Nanjing Medical University
See details and how to joinNCT07126678
Phase 1/2Taking people
Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).
Where
Beijing
Age
2 years to 90 years
People
75
Run by
Essen Biotech
See details and how to joinNCT06213636
Phase 1Not yet taking people in China
JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma
Where
Beijing
Age
18 years and over
People
20
Run by
Peking University Cancer Hospital & Institute
See details and how to joinNCT07024147
Phase 2Not yet taking people in China
Obinutuzumab With CHOP Versus Obinutuzumab With Bendamustine in the Treatment of Newly Diagnosed Follicular Lymphoma Grade 3A
Where
Guangzhou
Age
18 years and over
People
133
Run by
Sun Yat-sen University
See details and how to joinNCT06961500
Phase 2Taking people
Zanubrutinib Combined With G-CVP in Previously Untreated FL
Where
Beijing
Age
18 years to 80 years
People
40
Run by
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT06959732
Phase 2Not yet taking people in China
Zanubrutinib Plus GCVP (Obinutuzumab, Cyclophosphamide, Vindesine, Prednisolone) in Previously Untreated Follicular Lymphoma
Where
Hangzhou
Age
18 years to 80 years
People
58
Run by
Zhejiang Cancer Hospital
See details and how to joinNCT06918015
Phase 2Taking people
Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL
Where
Xiamen
Age
18 years to 70 years
People
38
Run by
The First Affiliated Hospital of Xiamen University
See details and how to joinNCT06151080
Phase 2Taking people
Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma
Where
Xiamen
Age
18 years and over
People
33
Run by
The First Affiliated Hospital of Xiamen University
See details and how to joinNCT06158386
Phase 2Taking people
Axicabtagene Ciloleucel Injection in Patients With Relapsed/Refractory Follicular Lymphoma
Where
Xiamen
Age
18 years and over
People
30
Run by
The First Affiliated Hospital of Xiamen University
See details and how to joinNCT06826118
Phase 2Not yet taking people in China
Efficacy and Safety of Zuberitamab Combined with Bendamustine, Followed by Monotherapy Maintenance, in Treatment-naïve Follicular Lymphoma
Where
Guangzhou
Age
18 years and over
People
50
Run by
Sun Yat-sen University
See details and how to joinNCT06757894
Phase 2Taking people
Radiotherapy Followed by Tiselizumab Combined With RCHOP in Previously Untreated Bulky Follicular Lymphoma
Where
Tianjin
Age
18 years to 70 years
People
20
Run by
Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT06704555
Phase 2Not yet taking people in China
Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR) in High-risk Treatment-naive Patients with Follicular Lymphoma (FL)
Where
Shanghai
Age
18 years and over
People
66
Run by
Ruijin Hospital
See details and how to joinNCT06549335
Phase 2Taking people
Zanubrutinib in Combination With Obinutuzumab (ZO) for Newly Diagnosed Follicular Lymphoma
Where
Xiamen
Age
18 years and over
People
39
Run by
The First Affiliated Hospital of Xiamen University
See details and how to joinNCT06553352
Phase 2Not yet taking people in China
A Phase II Study of SHR2554 in Patients With Relapsed or Refractory Follicular Lymphoma
Where
Beijing
Age
18 years and over
People
105
Run by
Jiangsu HengRui Medicine Co., Ltd.
See details and how to joinNCT06368167
No phaseNot yet taking people in China
Relmacabtagene Autoleucel in Hematologic Malignancies
Where
Beijing
Age
18 years and over
People
150
Run by
Shanghai Ming Ju Biotechnology Co., Ltd.
See details and how to joinNCT06142188
No phaseTaking people
A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL
Where
Shanghai
Age
18 years and over
People
332
Run by
Ruijin Hospital
See details and how to joinNCT05899621